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Abstract Autism is a neurodevelopmental disorder charac-
terized by three core symptom domains: ritualistic-repetitive
behaviors, impaired social interaction, and impaired commu-
nication and language development. Recent studies have
highlighted etiologically relevant recurrent copy number
changesinautism,suchas16p11.2deletionsandduplications,
aswellasasignificantroleforunique,novelvariants.Weused
Affymetrix 250K GeneChip Microarray technology (either
NspIo rStyI) to detect microdeletions and duplications in a
subset of children from the Autism Genetic Resource
Exchange (AGRE). In order to enrich our sample for
potentially pathogenic CNVs we selected children with
autism who had additional features suggestive of chromo-
somal loss associated with developmental disturbance
(positive criteria filter) but who had normal cytogenetic
testing (negative criteria filter). We identified families with
the following features: at least one child with autism who
also had facial dysmorphology, limb or digit abnormalities,
or ocular abnormalities. To detect changes in copy number
we used a publicly available program, Copy Number
Analyser for GeneChip® (CNAG) Ver. 2.0. We identified
novel deletions and duplications on chromosomes 1q24.2,
3p26.2, 4q34.2, and 6q24.3. Several of these deletions and
duplications include new and interesting candidate genes for
autism such as syntaxin binding protein 5 (STXBP5 also
known as tomosyn) and leucine rich repeat neuronal 1
(LRRN1 also known as NLRR1). Lastly, our data suggest that
rare and potentially pathogenic microdeletions and duplica-
tions may have a substantially higher prevalence in children
with autism and additional developmental anomalies than in







Autism (MIM 209850) is a neurodevelopmental disorder
characterized by three core symptom domains: ritualistic-
repetitive behaviors, impaired social interaction, and im-
paired communication and language [39]. The etiology of
autism appears to be primarily genetic, with karyotypically
detectable chromosomal abnormalities accounting for ~5–
7% of cases [22, 23, 36, 49]. Given that cytogenetic
analysis only detects abnormalities greater than 3–5 mega-
bases, however, it has been postulated that smaller
anomalies will also cause some proportion of autism. The
emergence of DNA microarray technology has enabled
detection of intermediate sized genomic variation, which
J Neurodevelop Disord (2009) 1:292–301
DOI 10.1007/s11689-009-9013-z
Electronic supplementary material The online version of this article
(doi:10.1007/s11689-009-9013-z) contains supplementary material,
which is available to authorized users.
L. K. Davis (*): K. J. Meyer:D. S. Rudd: A. L. Librant:
E. A. Epping:V. C. Sheffield: T. H. Wassink
Department of Psychiatry, University of Iowa,
Carver College of Medicine,
Iowa City, IA 52242, USA
e-mail: lea.k.davis@gmail.com
L. K. Davis: K. J. Meyer: V. C. Sheffield:T. H. Wassink
Interdisciplinary Genetics Program, University of Iowa,
Iowa City, IA 52242, USA
V. C. Sheffield
Howard Hughes Medical Institute, University of Iowa,
Iowa City, IA 52242, USAhas since been found to be both common and relevant to
human diseases, including autism [14, 28, 34, 41, 42].
Recent studies have also suggested a significant role for
CNVs, both de novo and inherited, in the etiology of autism
[3, 28, 30, 44, 50]. De novo copy number changes appear to
be particularly enriched in sporadic (simplex) autism, though
some recurrent CNVs that are primarily de novo,s u c ha s
16p11.2 deletions and duplications, are also occasionally
inherited from an unaffected parent, suggesting incomplete
penetrance for some autism-associated CNVs [3, 28, 50].
Several of the recently highlighted mutations in autism, such
as SHANK3 [7], NRXN1 [8, 19] and contactin 4 [38]h a v e
also been identified in parents, some of whom exhibit
features of a broader autism phenotype.
When interrogating a sample for CNVs, it is important to
notethatenrichment forde novo mutations in singleton families
is not specific to CNVs and that these families are likely to be
enriched for other types of sporadic mutations as well.
Chromosomal abnormalities (whether de novo or inherited)
have historically been associated with syndromic developmen-
tal delay such as 15q11-q13 syndrome, or the 22q11 group of
deletion disorders. Indeed, one of the first studies to identify
copy number variants in mental retardation selected for mental
retardation with syndromic presentation [15].
In order to enrich our sample for potentially pathogenic
chromosomal imbalances we applied a positive and negative
criteriafiltertothestudysample.Wehypothesizedthatchildren
with autism who had additional phenotypic features or
diagnoses suggestive of a developmental disturbance (positive
filter) but who had normal cytogenetic testing (negative filter)
would be more likely to harbor novel CNVs. We used this
model for two reasons: 1) children with chromosomal
abnormalities often have multiple or syndromic developmental
anomalies and 2) we recently reported a pathogenic micro-
deletion in a child with autism and eye abnormalities,
stimulating our interest in investigating other individuals with
autism and additional developmental disturbances [5]. While
the AGRE sample has been heavily studied, it is important to
note that many of the families included in this study have
been flagged as “possible non-idiopathic autism” by AGRE
due to their associated phenotypes, and therefore have been
generally excluded from previous linkage, association, and
CNV studies. In addition, we screened a sample of children
with autism and no dysmorphology from the AGRE cohort,
as well as a sample of unselected controls.
Methods
Patient ascertainment and sample
Families included in this study came from the Autism
Genetic Research Exchange. AGRE houses DNA and
phenotypic data on hundreds of simplex and multiplex
families of children with autism and makes these materials
available to researchers investigating autism. The diagnoses
were confirmed in the affected individuals through the
Autism Diagnostic Interview (ADI) and in some cases the
Autism Diagnostic Observation Schedule—General [6, 25,
26]. AGRE makes available to researchers data from family
medical and psychological history, physical exams, cytoge-
netic data, and findings from neurological exams.
From the AGRE repository of 814 multiplex and
simplex families, we identified a total of 17 children from
15 families with the following features: at least one child
with autism who also had a less than common cranio-facial
dysmorphology, limb or digit abnormality, or ocular
abnormality that were suggestive of a possible chromo-
somal imbalance. These children were considered the
“syndromic autism” sample and are referred to as such
throughout this paper. Included among these syndromic
features were microopthalmia, iris coloboma, trigonoce-
phaly, Sotos syndrome, cleft lip and palate, alopecia areata,
fused baby teeth, fused ribs, metatarsal full syndactyly of
toes 2,3 and 4 and adducted thumbs (Table 1). In families
AU0590 and AU0720 both affected siblings also showed
the same syndromic features. In the majority of cases, only
one affected sibling was included in the initial syndromic
autism group. In these cases, the affected sibling with
syndromic features was analyzed first and additional family
members (affected and unaffected) were studied as a
follow-up to compelling results. It should be noted that
the AGRE physical exam records indicate a number of
common and mild birth defects or abnormalities (i.e.
Strabismus, simple cutaneous syndactyly). These more
common features were not included in our study. We also
selected at random 19 subjects with autism and no
associated syndromic features from the AGRE cohort as a
comparison for the primary study sample.
In addition, we screened an unselected control popula-
tion of 716 individuals ascertained as part of a study of age-
related eye disease at the University of Iowa under the
direction of Dr. Edwin Stone. These individuals were
analyzed with either the 250K NspI and 250K StyI or the
5.0 Affymetrix SNP array platforms. The 250K array data
was also analyzed with CNAG while the 5.0 array data was
analyzed with dChip [24].
Affymetrix GeneChip® human mapping 250K microarray
DNA from each individual was analyzed with one of the
Affymetrix 250K GeneChip microarrays (either NspIo r
StyI). It is well documented that SNP genotyping arrays can
be used successfully for copy number detection [11, 31,
48]. The DNA was hybridized to the array according to the
manufacturer’s instructions. Briefly, the assay uses 250ng
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enzyme (New England Biolabs, Boston, MA), ligated to an
adaptor using T4 DNA ligase (New England Biolabs), and
amplified by PCR using Titanium Taq (Clonetech). PCR
products were then purified from excess primer and salts by
a DNA amplification cleanup kit (Clonetech) and a 90µg
aliquot was fragmented using DNaseI. An aliquot of the
fragmented DNA was separated and visualized in a 3%
agarose gel in 1× TBE buffer to ensure that the bulk of the
product had been properly fragmented. The fragmented
samples were end-labeled with biotin using terminal
deoxynucleotidyl transferase before each sample was
hybridized to the NspIo rStyI arrays for 16 h at 49°C.
After hybridization, the arrays were washed and stained using
an Affymetrix Fluidics Station 450. The most stringent wash
was 0.6× SSPE, 0.01% Tween-20 at 45°C, and the samples
were stained with R-phycoerythrin (Molecular Probes).
Imaging of the microarrays was performed using a
GCS3000 (Affymetrix) high-resolution scanner.
Detection of copy number variants
To detect changes in copy number we used a publicly
available program, Copy Number Analyser for GeneChip®
(CNAG) Ver. 2.0, developed at The University of Tokyo
[33]. CNAG was designed specifically for work with high-
density oligonucleotide arrays and uses a Hidden Markov
Model (HMM) to identify statistically significant deviations
in signal intensity between SNPs represented on the array.
Instead of using a standard reference panel, CNAG uses a
panel of “best fit” references. The reference arrays were
drawn from a pool of over 500 arrays of the same type
using the above methodology and run on individuals with
autism and their family members. Within this pool of
reference arrays the signal intensity standard deviation
values are ranked and the arrays with the best possible
standard deviation values are used for the analysis of each
new test array. Each array was referenced to at least 6 other
arrays of unrelated individuals. To determine CNV size we
relied primarily on boundaries defined by CNAG, though
with some deletions (Supplementary Table 1) we used loss
of heterozygosity (LOH) as determined by genotype data to
both validate the CNV and to better define the boundaries.
However, it should be noted that LOH is limited by the
presence of naturally occurring homozygous SNPs.
Identification and confirmation of CNVs of interest
All CNVs identified by CNAG in children with syndromic
autism as well as autism alone are described in supplemen-
tary materials (control data not included). To identify a
CNVof interest for follow-up validation and study, we first
ruled out common CNVs by comparison with the Database
of Genomic Variants CNV track on the May 2004 UCSC
Table 1 Children with autism and associated developmental abnormalities
Individual ID Phenotype of Affected Children Sibling Status
Ocular Sub-Phenotypes
AU033403 Autism, micropthalmia, syndactyly, MR Affected MZ twin, no syndromic features
AU1334302 Broad Spectrum, micropthalmia, MR Affected brother, no syndromic features
AU027505 Autism, micropthalmia Affected brother, no syndromic features
AU1376302 Autism, Iris coloboma Affected brother, no syndromic features
Cranio-facial Sub-Phenotypes
AU021903 Autism, Soto Syndrome, MR Two affected brothers,
no syndromic features
AU005303 Autism, alopecia areata Affected brother, no syndromic features
AU008404 Autism, trigonocephaly Affected brother, no syndromic features
AU028905 Autism, fused baby teeth Affected brother, no syndromic features
AU0875301 Autism, fused baby teeth Affected brother, no syndromic features
AU1437302 Autism, cleft lip and palate Affected brother, no syndromic features
Limb/Skeletal Sub-Phenotypes
AU067703 Autism, adducted thumbs, seizures, MR Affected brother, no syndromic features
AU059003 AU059004 Both affected children diagnosed with autism,
syndactyly of toes 2,3 and 4
AU067208 Autism, syndactyly of toes 2,3 and 4 Affected brother, no syndromic features
AU010903 Autism Spectrum, syndactyly of toes 2,3 and 4 Affected brother, fifth finger clinodactyly
AU072004 AU072005 Both affected children diagnosed with autism, fused ribs
*All samples listed have been tested by Karyotype and Fragile X testing
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addition, we used as a local comparison group the 716 eye
disorder controls. CNVs with more than one record in DGV
or any occurance in our own control sample were not
considered for follow-up. The decision to set the follow-up
threshold at one CNV occurrence in DGV control popula-
tions (instead of zero) was based on previous reports
suggesting that autism susceptibility CNVs may be present
at a very low frequency in a control population [50].
Among the CNVs that met these criteria, we identified and
validated by qPCR deletions and duplications that influ-
enced brain expressed genes of potential relevance to
autism. We then tested for segregation of the CNV with
disease in all available members of the proband’s family
using microarrays or qPCR.
For quantitative real-time PCR (qPCR), we selected an
amplicon within the center of the putative CNV. We used
an assay targeted for G6PD on the X-chromosome as an
internal control for gene dosage and an assay targeted for
GAPDH to normalize signal between DNA samples. As
the possibility for copy number variation exists for any
g i v e nr e g i o no ft h eg e n o m e ,w er e l i e do ni n f o r m a t i o n
obtained from our arrays as well as our gender prediction
within the qPCR experiment to support the use of GAPDH
as a normalization control for validation of copy number
variants. The reactions were performed in mixtures
containing 12.5µl of 2x QuantiTect SYBR Green PCR
Master Mix (QIAGEN), 12µl genomic DNA (1ng/µl),
0.25µl of each primer (10 pmol/µl) in a total volume of 25
µl. The PCR amplification and detections were carried out
in an ABI 7700, each with an initial activation step for
15 min at 95ºC followed by 15s at 94ºC, 30s at 55ºC, and
30s at 72ºC for 42 cycles. Each experiment was performed
two times with three replicates in each experiment. To
exclude the presence of non-specific products, a melting
curve analysis was performed. The threshold cycle value
was calculated using the comparative CT method. CT was
determined using the thermocycler software and an
average of the three replicates was calculated. The fold
change from normal samples was set at 1 and the ratio of
the normalized fold change in autism compared to that of
control samples was calculated.
Direct sequencing
Direct sequencing was used for identification of possible
compound heterozygous mutations in one family in which a
CNV affecting a single gene (STXBP5) was identified.
Additionally, direct sequencing was used to rule out a PAX6
mutation in a child with coloboma of the iris and autism. All
STXBP5 and PAX6 exons were forward and reverse
sequenced in families AU0677 and AU1376, respectively.
The sequence data were analyzed using the Sequencher gene
analysis computer program (Gene Codes, Ann Arbor, MI).
Results
In our sample of 17 children with syndromic autism, we
detected an average of 3.1 CNVs per child including 31
deletions and 21 duplications (Table 2), a rate similar to that
from previous studies of autism using similar methodolo-
gies [28]. Nine CNVs were novel with five being of
particular interest (Table 3). The pedigrees of the families
highlighted in the results are shown in Fig. 1. In the sample
of 19 children with non-syndromic autism we detected an
average of 3.4 CNVs per child including 33 deletions and
32 duplications (Table 2). Two CNVs were novel and one
was of high interest (Table 3). The two groups did not differ
in their average number of CNVs per individual. A fisher’s
exact test of the number of novel CNVs out of the total
number of CNVs in each group yields a one-tailed p-value
of .04, suggesting that there are significantly more novel
CNVs in the sample of children with syndromic autism.
However, the number of individual carriers of novel CNVs
did not differ significantly between the groups as there were
two individuals in the syndromic autism group who each
carried two novel CNVs (Table 4).
Syndromic Autism Non-Syndromic Autism
Deletions Duplications Deletions Duplications
Count 31 21 33 32
Mean Size (bp) 285,162 515,387 506,285 539,957
Standard Deviation (bp) 225,908 515,710 564,239 596,016
Median Size (bp) 247,667 279,487 177,559 302,457
Minimum Size (bp) 8,019 38,289 8,827 52,037
Maximum Size (bp) 1,068,599 1,686,125 1,896,864 1,896,864
Table 2 Size of CNVs in
children with syndromic autism
and children with autism only
The descriptive statistics listed
include children with syndromic
autism and non-syndromic au-
tism that were analyzed with
either the NspIo rStyI 250K
SNP microarray. These statistics
do not include siblings or
parents
J Neurodevelop Disord (2009) 1:292–301 295Fig. 1 Pedigrees of families with syndromic autism and copy number
variants of high interest. Asterisks indicate parent of CNV origin.
Hatched individuals have been diagnosed with an autism spectrum
disorder while those in solid shading have been diagnosed with
autism. a Deletion on chromosome 6q24 was identified in AU067703
and was inherited maternally from AU067701. AU067703 is
diagnosed with autism, seizures, mental retardation and adducted
thumbs while AU067705 is diagnosed with autism only. Their mother
has been diagnosed with bipolar disorder. b Deletion on chromosome
1q24.2 was identified in AU1334302 and AU1334303 and was
transmitted by AU1334201. Additionally AU1334303 carries another
duplication on chromosome 22q11.21 that was not paternally
inherited. DNA from AU1334202 was unavailable for testing. c A
paternally inherited duplication on chromosome 4q34.2 was identified
in individuals AU010903 and AU010904. d Two paternally inherited
duplications on chromosome 3p26.2 and 3p26.1 were present in
individuals AU005303 and AU005304. Additionally AU005304
carried a small, apparently de novo duplication on chromosome
3p25.1







































Yes N/A Paternal qPCR
AU0677 03 Adducted
Thumbs
Del 261 6q24.3 STXBP5 No No Maternal qPCR/LOH
AU0109 04 Clinodactyly Dup 166 4q34.3 WDR17,
SPATA4,
ASB5
Yes No Paternal qPCR
AU1334 302 Microphthalmia Del 317 1q24.2 XCL1,
XCL2,
DPT
Yes No Paternal qPCR/LOH
AU0383 03 none Del 177 7q35 CNTNAP2 No N/A Paternal qPCR
Individuals listed (unless otherwise noted) were diagnosed with primary autism and have secondary developmental abnormalities according to
physical exams and medical records collected by AGRE. Further information about these families is available in the supplementary materials of
this paper
296 J Neurodevelop Disord (2009) 1:292–301CNVs of interest identified in children with syndromic
autism
Pedigrees for families with CNVs of interest are provided
in Fig. 1 and CNV diagrams are provided in Fig. 2.W e
identified a 260 kb deletion on chromosome 6q24 in a
family with two affected boys and one unaffected girl. The
oldest affected boy, who carried the deletion, was diag-
nosed with autism, mental retardation and seizures. The
deletion was also detected in the mother who has severe
bipolar disorder with episodes of psychosis and suicidal
ideation. This deletion contained coding sequence from
only one gene on chromosome 6q24, syntaxin binding
protein 5 (STXBP5). This deletion was not present in the
mildly affected brother or unaffected sister. STXPB5 was
also sequenced in this family to rule out the possibility of a
compound heterozygous mutation, with no new SNPs or
mutations being identified. We also detected a 317 kb
deletion on chromosome 1q24.2 in two siblings with autism
spectrum disorders, one of whom had an additional
phenotype of microphthalmia. The deletion was transmitted
from the father and was not present in an unaffected
paternal half-brother. The father transmitting the deletion
has been diagnosed with depression, anxiety disorder, and
ADHD. This deletion is novel and contains three genes,
dermatopontin (DPT), chemokine (C motif) ligand 1, and
chemokine (C motif) ligand 2. A 166 kb deletion on
chromosome 4q34.2 was identified in two of three
trizygotic triplets. The two children carrying the 4q34.2
deletion have autism and malformations of the limbs. One
twin has finger clinodactyly on both hands while the other
has metatarsal syndactyly of toes 2, 3 and 4 on both feet.
This deletion was paternally inherited and not present in the
third unaffected triplet. The father reported learning
disabilities as a child and his sister has mild mental
retardation. This deletion includes three known genes, WD
repeat domain 17 (WDR17), spermatogenesis associated 4
(SPATA4),a n dankyrin repeat and SOX box containing
protein 5 (ABS5). Deletions in this chromosome region
have previously been associated a number of features
including mild mental retardation, velo-cardio-facial
(VCF) syndrome-like features, and finger clinodactyly
[16, 45, 47]. While there are no clear features of VCF in
this family, the affected children do display the 4q34.2
characteristic digit abnormalities. In family AU0053 we
identified two duplications in close proximity to each other
on chromosome 3p26.2-p26.1 in a family with two affected
brothers. This family has been recently published in
Christian et al. [3] and here we add to their findings and
further discuss the candidate interval. The father, who
transmitted the duplications, endorsed symptoms of
obsessive-compulsive disorder (OCD) and attention
deficit-hyperactivity disorder (ADHD) and is a self-
described loner. The duplication that brought this family
to our attention is located on 3p26.1, is 137 kb in length,
contains no genes, and is entirely novel. The second
duplication on this chromosome lies on 3p26.2 and is
approximately 2 Mb telomeric to the first duplication.
CNVs overlapping with this duplication on 3p26.2 have
been identified in three unselected controls [18, 34]. The
duplication on 3p26.2 is 336 kb in length and contains a
portion of only one validated gene, leucine rich repeat
neuronal 1 (LRRN1). It is worth noting that according to the
microarray analysis, the breakpoints for this CNV, which are
novel to DGV, fall within the LRRN1 gene itself suggesting
possible disruption of the transcriptional unit. Finally, a
177 kb deletion on chromosome 7q35 was detected in one
male child with autism and no related dysmorphology, but
was not identified in his younger affected brother. This
deletion encompasses a portion of the first intron of
CNTNAP2 and was previously identified in [1]. The deletion
was paternally inherited and while the father did not report
any learning disorders he did report a lack of empathy and
considers himself “eccentric and a loner”.
Discussion
This study was designed to identify CNVs that may play a
role in the etiology of autism. We applied positive and
Table 4 Statistical Comparisons of CNVs between syndromic autism and non-syndromic autism groups
Comparison Groups Number in each group out of total Test of Significance
Syndronic Autism Autism Only
Novel CNV carriers with syndromic features vs. Fisher’s Exact
Novel CNV carriers without syndromic features 5/17 2/19 p=.15
Novel CNVs in syndromic autism group vs. Fisher’s Exact
Novel CNVs in “autism only” group 7/52 2/65 p=.04
Average number of CNVs in syndromic autism group vs. Student’s T-Test
Average number of CNVs in autism only group 3.12 (± 1.36) 3.42 (± 2.59) p=.67
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Fig. 2 UCSC Genome Browser May 2004 screen captures of novel
structural variants [17] in individuals with syndromic autism (http://
genome.ucsc.edu). a Deletion identified in two affected siblings (one
with microopthalmia), AU1334303 and AU1334302. The deleted
region on chromosome 1q24.2 includes the genes XCL2 and DPT. b
Deletion identified in one affected proband (with microopthalmia)
AU027505. As no genes lie within the deletion region, this CNV did
not meet our criteria for continued study and additional family
members were not screened. The deleted region on chromosome
2p22.1 is non-genic, however, it is notable that region appears to
contain conserved elements and is within close proximity of the gene
SLC8A1. c Duplications were identified in two affected siblings (one
with alopecia), AU005303 and AU005304. The duplicated regions on
chromosome 3p26.2 and 3p26.1 overlap with LRRN1 and lie close to
CNTN4 and GRM7. d Duplication identified affected siblings (one
with syndactyly, the other with clinodactyly) AU010903 and
AU010904. The duplicated region on chromosome 4q34.2 encom-
passes two genes, WDR17 and ABS5. e Deletion identified in one
affected sibling (with adducted thumbs), AU067703. The deleted
region on chromosome 6q24.3 includes STXBP5. f Second duplication
identified in individual AU1334302. The duplicated region on
chromosome 22q11.21 includes a number of genes and overlapping
regions of common variation, however, the breakpoints identified in
AU1334302 are unique to the Database of Genomic Variants and
include genes such as SNAP29 that do not show evidence of common
variation
298 J Neurodevelop Disord (2009) 1:292–301negative filter criteria to AGRE families in order to enrich
our sample for such CNVs. We theorized that children
with autism and additional developmental anomalies
would be more likely than children with idiopathic autism
to harbor pathogenic microdeletions and duplications. We
did not find significant enrichment of de novo CNVs,
however, we did identify significantly more rare inherited
CNVs in our sample of syndromic autism compared to a
sample of non-syndromic autism. It is worth mentioning
that almost all of the rare, inherited, CNVs were
transmitted from parents reporting a range of learning
disabilities and psychiatric disturbance. We highlight
novel deletions and duplications on chromosomes
1q24.2, 3p26.2, 4q34.2, 6q24.3, and 7q35. It is important
to note that with increased array density, it is possible that
some of the highlighted novel CNVs will be identified in
control populations. The “novel” status of CNVs is rather
a moving target and even during the preparation of this
manuscript, CNV status had to be changed. While this
data is preliminary and should be interpreted with caution,
several of the deletions and duplications reported here
include new and interesting biological candidate genes for
autism such as syntaxin binding protein 5 (STXBP5 also
known as tomosyn), and leucine rich repeat neuronal 1
(LRRN1 also known as NLRR1).
Perhaps the most compelling of these is STXBP5,
which plays a key role in neuronal guidance and in
regulation of synaptic transmission at the presynaptic cleft
[51]. The protein forms a stable t-SNARE complex with
SNAP-25 and a ROCK/Rho phosphorylated form of
synatxin-1 (isoforms A and B) at the presynaptic nerve
terminal. Its interaction with SNAP-25 and syntaxin-1
ultimately blocks synaptobrevin (part of the v-SNARE
machinery) from joining the SNARE complex, resulting
in inhibition of vesicle exocytosis [10, 12, 51]. This
synaptic vesicle inhibition is particularly important in
early development during extension and retraction of
neurites. Phoshorylated syntaxin-1 and STXBP5 have
been shown to co-localize to the palm of the growing
neurite, thereby inhibiting synaptic formation along the
palm and encouraging synaptic vesicle release toward the
growth cone of the emerging dendrite or axon [40, 51].
Ours is the first mutation reported of STXBP5,p r e s e n ti na
mother with severe bipolar disorder and her son with
autism, mental retardation and seizures. A recent paper
has suggested syntaxin-1A as a possible autism candidate
based on SNP genotype association with autism in a set of
AGRE trios as well as mRNA expression data that
suggests syntaxin-1A is expressed at a higher level in
children with high functioning autism than in age and
gender matched controls [32]. It is also important to note
that one child with autism spectrum disorder in this
family did not carry the STXBP5 deletion. This phenom-
enon has been noted in previous studies of autism
susceptibility genes [28, 50]. It is possible that the
STXBP5 deletion is not causative but influences autism
severity, that there is a secondary cause for autism in the
sibling, or that STXBP5 has an additional maternal mRNA
contribution during fetal development that resulted in a
more severe form of autism in the sibling who was also
carrying the deletion.
Duplications flanking the neuronal cell adhesion
molecule LRRN1 were detected in a second family. One
of the duplications has unique breakpoints disrupting the
only intron of LRRN1. It is unclear whether these
duplications are functionally connected or arose indepen-
dently, but the possibility remains that they may act in
concert in this family. Leucine rich repeat neuronal genes
are heavily expressed during embryonic development of
the cortex and are thought to be involved in neuronal
outgrowth. However, their role in synaptic cell adhesion is
still unclear [20, 21]. Mutations in LRRN1 have not been
associated with any other disorder, though mutations in
the LRRN gene family have been associated with other
psychiatric disorders such as Parkinson’s disease and
schizophrenia [9, 27]. Additionally, larger deletions and
duplications of chromosome 3p26 have been found in
children with Prader-Willi syndrome, mental retardation,
and social cognition deficits [2, 37]. Recently, deletions in
another cell adhesion molecule, contactin 4, were identi-
fied in three children with autism. [3].
One limitation of our study is the possibility that our
findings may be associated with the additional phenotype
and not autism in these individuals. We believe this to be
unlikely, however, as the chromosomal abnormalities that
we identified disrupt compelling biological candidates
that are heavily expressed in the brain and known to
function at the neuronal synapse. We believe it is more
likely that these CNVs have a pleiotropic effect based on
gene dosage or position of the chromosomal disruption. In
addition we were unable to entirely rule out cell line
effects; however, as the CNVs highlighted in the results
were all inherited, they are unlikely to represent such
artifacts.
Lastly, our data suggest that rare microdeletions and
duplications may have a statistically higher occurrence in
children with autism and additional developmental anoma-
lies and that these children ought not be excluded from
studies of copy number variants in autism. Here we present
evidence from such a sample, implicating new genes such
as STXBP5 and LRRN-1 that may play a role in the
development of autism. While the results presented here
require further investigation in larger samples, it may also
be prudent to consider clinical high density microarray
testing for children who present with autism and related
developmental disturbances.
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